Clinical Trials Browser

Phase NA × NETWORK × Fallopian Tube Neoplasms × Clear all

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00499291 2023-05-25

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Teratoma, Testicular, Teratoma, Ovarian, Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Teratoma, Testicular Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT00958698 2019-03-12

Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase NA Unknown

485 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01275664 2018-05-22

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

Phase NA Terminated

4 enrolled 5 charts

Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Nausea, Ovarian Neoplasms, Vomiting

NCT00551265 2017-07-14

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

Phase NA Withdrawn

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Clinical Trials

Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors

Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy